Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor

Detalles Bibliográficos
Autores principales: Wierda, William G., Byrd, John C., Davids, Matthew S., Furman, Richard R., Cheson, Bruce D., Barr, Paul M., Eradat, Herbert, Heffner, Leonard, Zhou, Lang, Verdugo, Maria, Potluri, Jalaja, Choi, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587980/
https://www.ncbi.nlm.nih.gov/pubmed/30478940
http://dx.doi.org/10.1111/bjh.15666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587980/
https://www.ncbi.nlm.nih.gov/pubmed/30478940
http://dx.doi.org/10.1111/bjh.15666

Ejemplares similares